Guerbet

58 articles about Guerbet

• 

  BioSpace Movers & Shakers, Dec. 20

  12/20/2019

  Pharma, biotech and life sciences organizations strengthen their leadership teams and boards.
• 

  BioSpace Global Roundup, Nov. 21

  11/21/2019

  Companies from across the globe provide updates on their businesses and pipelines.
• 

  BioSpace Global Roundup, Oct. 17

  10/17/2019

  Companies from across the globe provide business and pipeline updates.

• Guerbet and IBM Watson Health announce a second co-development project as part of their strategic partnership for leveraging artificial intelligence in medical imaging

  9/24/2019

  This second agreement is aimed at developing and marketing a software solution to help radiologists and oncologists diagnose and monitor prostate cancer

• Guerbet announces group purchasing agreement with Premier to distribute novel microcatheters

  6/18/2019

  Guerbet LLC USA announced a group purchasing agreement with Premier Inc., a leading healthcare improvement company for Guerbet's SeQure and DraKon, two novel microcatheters intended for the infusion of therapeutic agents, contrast media and embolics into peripheral vessels.

• Guerbet Announces Transition from Temporary Importation to Regular Supply for Lipiodol® (ethiodized oil) Injection; also introduces new glass vial container - April 1, 2019

  4/1/2019

  U.S. manufacturing change from ampoules to vials reflect Guerbet's commitment to patient safety and innovation in contrast imaging

• Guerbet to present its innovative solutions offering for interventional imaging at CIRSE 2018

  9/20/2018

  Guerbet, the global specialist in contrast media and solutions for diagnostic and interventional medical imaging, has announced its presence at the 2018 annual congress of the CIRSE (Cardiovascular & Interventional Radiological Society of Europe), to be held from September 22 to 25, 2018 in Lisbon (Portugal). 

• Guerbet Announces Commercial Partnership With Imalogix™ to Deliver Diagnostic and Interventional Imaging Care Optimization

  8/13/2018

  Guerbet LLC USA announced today a commercial partnership with Imalogix™, a leader in artificial intelligence process and workflow solutions.

• Guerbet Announces AHRA Charitable Contribution to Support Next Generation Leaders in Medical Imaging

  7/24/2018

  Guerbet LLC USA announced a contribution of $50,000 to the Association for Medical Imaging Management (AHRA) "Defining Our Future" campaign

• Guerbet Unveils L-F Hydra Vision™ Digital Urological Imaging System

  5/29/2018

  Guerbet LLC USA announced the launch of the L-F Hydra Vision™ Digital Imaging System.

• 

  Guerbet Pays $23.7M for Israeli Medtech Accurate Medical Therapeutics

  1/12/2018

  Accurate has developed a range of microcatheters for embolization procedures of tumors and vascular aneurysms.

• GUERBET : Gadolinium-Based Contrast Agents: Update on MHLW Decision in Japan

  12/7/2017

  For all GBCAs, "the necessity of MRI scan using gadolinium-based contrast agents should be determined carefully" as stated in the Japanese new package insert.

• Guerbet Reinforces its Expertise With the Launch of Contrast&Care, a Contrast Media Injection Management Solution for Radiology Centers

  11/27/2017

  The launch of the solution is part of the strategy of Guerbet to develop a portfolio of digital solutions to optimize the care and management of patients by healthcare professionals.

• Guerbet To Take Part In The 65th Edition Of The Journées Francophones de Radiologie Diagnostique et Interventionnelle (JFR)

  10/9/2017

• Guerbet Announces CE Mark For Vectorio, An Innovative Medical Device For cTACE Procedures

  9/14/2017

• Guerbet Statement Following FDA Medical Imaging Drugs Advisory Committee September 8, 2017

  9/11/2017

• FDA Approves Guerbet's Dotarem (Gadoterate Meglumine) For Pediatric Patients Younger Than Two Years

  9/6/2017

• Guerbet: Revenue At June 30, 2017

  7/27/2017

• Guerbet Invests In The Truffle Capital Fund Dedicated To Medical Devices And Biotechnologies

  6/14/2017

• Guerbet Concurs With The PRAC Recommendations On Gadolinium-Based Contrast Agents And Announces Changes To The US Labeling For Its Linear Agent Optimark (Gadoversetamide Injection)

  3/31/2017